Last Price$488.3(2.3%)
Market Cap$124.8B
LTM Capital Expenditure
($297.7M)
YoY Growth
+15.2%
3Y CAGR
+8.2%
5Y CAGR
+31.6%
Stock quality & Intrinsic value
6/10
61.6% overvalued
Vertex Pharmaceuticals Incorporated Capital Expenditure
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | ($17.0M) | ($32.4M) | ($32.4M) | ($32.2M) | ($23.5M) | ($38.1M) | ($94.6M) | ($71.1M) | ($51.4M) | ($51.2M) | ($45.3M) | ($56.6M) | ($259.4M) | ($95.5M) | ($75.5M) | ($259.8M) | ($235.0M) | ($204.7M) | ($258.4M) | ($297.7M) |
Overvalued or undervalued?
Check the intrinsic value for VRTX
and see if it's the right time to invest.
Vertex Pharmaceuticals Incorporated (VRTX) Capital Expenditure comparison analysis
General
LTM Capital Expenditure
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Vertex Pharmaceuticals IncorporatedVRTX
($297.7M)
15.2%
8.2%
31.6%
Median Peer Set
($98.8M)
0.3%
(3.3%)
8.8%
Royalty Pharma plcRPRX
$0.0
N/A
N/A
N/A
Summit Therapeutics Inc.SMMT
($138.8K)
8.5%
(23.2%)
(13.4%)
Alnylam Pharmaceuticals, Inc.ALNY
($34.3M)
(44.9%)
(23.4%)
(24.5%)
argenx SEARGX
($65.7M)
(37.0%)
(19.6%)
12.5%
BioMarin Pharmaceutical Inc.BMRN
($97.4M)
(9.5%)
(6.5%)
(9.8%)
Incyte CorporationINCY
($100.2M)
110.9%
(17.9%)
5.1%
United Therapeutics CorporationUTHR
($246.5M)
7.0%
26.8%
24.1%
BioNTech SEBNTX
($489.9M)
(35.8%)
43.3%
44.8%
BeiGene, Ltd.BGNE
($603.6M)
0.7%
41.5%
23.9%
Regeneron Pharmaceuticals, Inc.REGN
($823.3M)
5.5%
14.3%
13.9%
VRTX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 160.9 56.6% | 216.4 34.5% | 199.0 (8.0%) | 175.5 (11.8%) | 102.0 (41.9%) | 143.4 40.5% | 1,410.6 883.9% | 1,527.0 8.3% | 1,212.0 (20.6%) | 580.4 (52.1%) | 1,032.3 77.9% | 1,702.2 64.9% | 2,488.7 46.2% | 3,047.6 22.5% | 4,162.8 36.6% | 6,205.7 49.1% | 7,574.4 22.1% | 8,930.7 17.9% | 9,869.2 10.5% | 11,020.1 11.7% |
| Cost of Goods Sold (COGS) | 10.1 | 12.2 | 13.9 | 15.7 | 14.2 | 12.7 | 80.5 | 279.9 | 130.3 | 61.0 | 125.5 | 210.5 | 275.1 | 409.5 | 547.8 | 736.3 | 904.2 | 1,080.3 | 1,262.2 | 1,530.5 |
% margin | 150.8 93.7% | 204.2 94.4% | 185.1 93.0% | 159.8 91.1% | 87.8 86.1% | 130.6 91.1% | 1,330.1 94.3% | 1,247.2 81.7% | 1,081.7 89.3% | 519.4 89.5% | 906.8 87.8% | 1,491.7 87.6% | 2,213.5 88.9% | 2,638.1 86.6% | 3,615.1 86.8% | 5,469.4 88.1% | 6,670.2 88.1% | 7,850.4 87.9% | 8,607.0 87.2% | 9,489.6 86.1% |
| Operating Expenses | 292.5 | 429.6 | 597.8 | 618.2 | 680.0 | 825.2 | 1,108.4 | 1,243.0 | 1,281.1 | 1,160.9 | 1,373.3 | 1,480.5 | 1,820.7 | 1,974.1 | 2,413.0 | 2,600.0 | 3,891.2 | 3,485.0 | 4,775.0 | 9,722.5 |
| Research & Development Expenses (R&D) | 248.5 | 371.7 | 513.1 | 516.3 | 550.7 | 637.4 | 707.7 | 806.2 | 918.8 | 855.5 | 996.2 | 1,047.7 | 1,324.6 | 1,416.5 | 1,754.5 | 1,829.5 | 3,051.1 | 2,540.3 | 3,162.9 | 3,630.3 |
| Selling, General & Administrative Expenses (SG&A) | 44.0 | 57.9 | 84.7 | 101.9 | 129.3 | 187.8 | 400.7 | 436.8 | 362.3 | 305.4 | 377.1 | 432.8 | 496.1 | 557.6 | 658.5 | 770.5 | 840.1 | 944.7 | 1,136.6 | 1,464.3 |
% margin | (149.9) (93.2%) | (229.0) (105.9%) | (419.8) (210.9%) | (462.7) (263.6%) | (613.4) (601.1%) | (696.1) (485.5%) | 113.8 8.1% | 2.3 0.2% | (903.4) (74.5%) | (692.4) (119.3%) | (468.7) (45.4%) | 9.9 0.6% | 123.2 5.0% | 635.2 20.8% | 1,197.6 28.8% | 2,856.3 46.0% | 2,782.1 36.7% | 4,307.4 48.2% | 4,307.5 43.6% | (232.9) (2.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 16.3 | 5.0 | 2.0 | 1.9 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 11.7 | 0.0 | 63.7 | 22.2 | 4.9 | 144.6 | 614.7 | 598.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 13.5 | 13.2 | 19.3 | 36.6 | 14.7 | 22.7 | 72.9 | 84.2 | 81.4 | 57.6 | 34.1 | 58.5 | 58.2 | 61.5 | 54.8 | 44.1 | 30.6 |
| Pre-tax Income | (173.4) | (206.9) | (426.9) | (464.2) | (642.2) | (754.6) | 60.4 | (12.4) | (976.1) | (734.9) | (559.6) | (67.4) | (15.7) | 600.2 | 1,394.9 | 3,116.8 | 2,730.4 | 4,232.4 | 4,379.8 | 248.5 |
% effective tax rate | 61.7 (35.6%) | (18.5) 8.9% | (21.4) 5.0% | (30.7) 6.6% | 19.3 (3.0%) | 19.3 (2.6%) | 19.3 31.9% | 38.8 (313.0%) | (288.6) 29.6% | 7.0 (0.9%) | 30.4 (5.4%) | 16.7 (24.7%) | (107.3) 684.1% | (1,486.9) (247.7%) | 218.1 15.6% | 405.2 13.0% | 388.3 14.2% | 910.4 21.5% | 760.2 17.4% | 784.1 315.5% |
% margin | (203.4) (126.4%) | (206.9) (95.6%) | (391.3) (196.6%) | (459.9) (262.0%) | (641.6) (628.7%) | (754.6) (526.3%) | 29.6 2.1% | (107.0) (7.0%) | (445.0) (36.7%) | (738.6) (127.2%) | (558.1) (54.1%) | (112.1) (6.6%) | 263.5 10.6% | 2,096.9 68.8% | 1,176.8 28.3% | 2,711.7 43.7% | 2,342.1 30.9% | 3,322.0 37.2% | 3,619.6 36.7% | (535.6) (4.9%) |
| EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.32) | (0.46) | 1.06 | 8.25 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | (2.08) |
| Diluted EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.31) | (0.46) | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | (2.08) |
% margin | (114.4) (71.1%) | (199.5) (92.2%) | (385.2) (193.6%) | (426.2) (242.8%) | (598.9) (586.9%) | (704.9) (491.7%) | 133.9 9.5% | 42.5 2.8% | (554.8) (45.8%) | (598.8) (103.2%) | (411.3) (39.8%) | 75.5 4.4% | 103.3 4.1% | 706.8 23.2% | 1,560.4 37.5% | 3,284.5 52.9% | 2,917.5 38.5% | 4,435.5 49.7% | 4,605.2 46.7% | 486.3 4.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Vertex Pharmaceuticals Incorporated's Capital Expenditure?
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Capital Expenditure is ($297.7M), based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Vertex Pharmaceuticals Incorporated's Capital Expenditure growth rate?
Over the last year, Vertex Pharmaceuticals Incorporated's Capital Expenditure growth was 15.2%. The average annual Capital Expenditure growth rates for Vertex Pharmaceuticals Incorporated have been (4.6%) over the past three years, 31.6% over the past five years.
3) Is Vertex Pharmaceuticals Incorporated's Capital Expenditure growth rate Good?
Over the last year, Vertex Pharmaceuticals Incorporated's Capital Expenditure growth was 15.2%, which is higher than industry growth of (0.6%). It indicates that Vertex Pharmaceuticals Incorporated's Capital Expenditure growth is Bad.